Retatrutide and trizepatide represent a novel class of medications that act on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists https://janaivtp805925.bluxeblog.com/70870056/new-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide